1. Home
  2. Live Updates
  3. Ancer of the lung

Live Breaking News & Updates on Ancer of the lung

Stay informed with the latest breaking news from Ancer of the lung on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Ancer of the lung and stay connected to the pulse of your community

Definitive Therapy Ups Survival in Brain-Only Mets NSCLC

Definitive treatment to the primary site improves overall and cancer-specific survival among patients with brain-only NSCLC metastases, a recent retrospective study shows.

Royal-oak , Michigan , United-states , American , Kamran-salari , Corewell-health-east-william-beaumont-university-hospital , American-society-of-radiation-oncology , American-society , Radiation-oncology , Lung-cancer , Ung-carcinoma , Ancer-of-the-lung

Is the FDA Pausing More Cancer Trials? It's Hard to Tell

Clinical trial holds delay therapies getting to market and may be on the rise in oncology. But there's a lot the public doesn't know about how often these holds happen and why.

United-states , Boston , Massachusetts , Washington , American , Matthewe-brown , Joshua-sharfstein , Derek-scholes , Nelson-mullins , Julier-gralow , Johns-hopkins-bloomberg-school-of-public-health , American-society-of-clinical-oncology

Is Osimertinib Better Alone or With Chemotherapy in NSCLC?

A new study reveals that baseline EGFR mutations may be key to making the decision in the frontline setting.

Boston , Massachusetts , United-states , Illinois , University-of-chicago , Chicago , Dana-farber-cancer-institute , San-diego , California , American , Marina-garassino , Clinical-research-annual-meeting

Why Lung Cancer Screening Is Not for Everyone

Many patients undergo lung cancer screening despite having a higher likelihood of experiencing harm rather than benefit.

United-states , Milan , Lombardia , Italy , Italian , Alessandro-pardolesi , National-cancer-institute , Veterans-health-administration , Family-medicine , Rete-italiana-screening-polmonare , Lung-cancer , Ung-carcinoma

ICI Tx in MS Patients With Comorbid Cancer: Reassuring Data

There is no increased relapse risk in patients with multiple sclerosis and comorbid cancer who are taking checkpoint inhibitor therapy, results of a small study suggest.

Massachusetts , United-states , Boston , Jordan , American , Prashanth-rajarajan , Department-of-neurology , Harvard-medical-school , American-academy-of-neurology , Medscape-medical , American-academy , Medscape-medical-news

Ovarian Cancer: Another Promising Target for Liquid Biopsy

A blood test to screen for ovarian cancer is one of many new liquid biopsy assays being evaluated to screen for cancer.

Baltimore , Maryland , United-states , New-haven , Connecticut , Johns-hopkins-university , Yale-university , American , Victor-velculescu , Roy-herbst , Oncology-at-yale-university , American-association-for-cancer-research

Novocure's Lung Cancer Device Slows Progression to Brain in Trial, Shares Rise

Novocure said on Wednesday that its device met the main goal of a late-stage trial by slowing the progression of cancer to the brain in patients with a type of lung cancer,...

Bengaluru , Karnataka , India , Shounak-dasgupta , Shailesh-kuber , Puyaan-singh , Reuters , Tumor-treating-fields , Treating-fields , Lung-cancer , Ung-carcinoma , Ancer-of-the-lung

Subcutaneous Immunotherapy: Better Life for Cancer Patients

Administering immunotherapy via subcutaneous infections could save clinicians time and money and patients may prefer it.

Toronto , Ontario , Canada , Rome , Lazio , Italy , Ireland , Genentech-roche , Natasha-leighl , Hazel-osullivan , Federico-cappuzzo , Cork-university

Continued Benefit, More Toxicity With Osimertinib-Chemo

Patients with advanced EGFR-mutated NSCLC who were given osimertinib plus chemotherapy up front continue to show improved outcomes after initial progression, suggests ongoing trial data.

Netherlands , Peru , Lima , Amsterdam , Noord-holland , Natalia-isabel-valdiviezo-lama , Netherlands-cancer-institute , Drug-administration , National-institute-of-neoplastic-diseases , European-lung-cancer-congress , National-institute , Neoplastic-diseases

Does Neoadjuvant Chemoimmunotherapy Boost Survival in NSCLC?

A meta-analysis confirms that neoadjuvant chemoimmunotherapy improves survival outcomes in most patients with resectable NSCLC, except for overall survival in patients with baseline PD-L1 below 1%.

Quebec , Canada , Mark-sorin , Mcgill-university , Morris-goodman-cancer-institute , European-medicines-agency , Drug-administration , European-medicines , Non-small-cell-lung-cancer , Sclc , Lung-cancer , Ung-carcinoma